What development phase is Ethenzamid in?

Ethenzamid is FDA-approved (marketed).

What is the generic name of Ethenzamid?

ETHENZAMIDE is the generic (nonproprietary) name of Ethenzamid.

Last reviewed 2026-04-20 · How we verify

Ethenzamid (ETHENZAMIDE)

FDA-approved active Small molecule Quality 6/100

Ethenzamide is a marketed drug with an unspecified primary indication, operating in a competitive landscape dominated by off-patent alternatives such as acetylsalicylic acid, salicylamide, salsalate, and diflunisal. Its key strength lies in the protection of its composition patent, which remains valid until 2028, providing a barrier to generic competition. The primary risk is the strong presence of established, off-patent competitors, which may limit Ethenzamide's market share and revenue potential.

At a glance

Generic name	ETHENZAMIDE
Drug class	ethenzamide
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ethenzamid CI brief — competitive landscape report
Ethenzamid updates RSS · CI watch RSS